WHO ICTRP trial
Prevention of childhood asthma using house dust mite allergen tablets
ISRCTN14917997 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN14917997 |
|---|---|
| Public title | Prevention of childhood asthma using house dust mite allergen tablets |
| Scientific title | Preventing childhood Asthma using Prophylactic house dust mite Allergen immunotherapy |
| Primary sponsor | University of Southampton |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | England;Scotland;United Kingdom |
| Conditions | Paediatric asthma Respiratory |
| Interventions | Active intervention: Acarizax (12 SQ-HDM SLIT). Control: Placebo. Dose: 30 µg. Dose frequency: Once daily. Route of administration: Sublingual. All infants will be reviewed every 6 weeks by telephone/video call, in the first year and then… |
| Registration date | Nov 9, 2025 |
| Target size | 434 |
| Secondary IDs | Nil known;Nil known;89828 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: